# Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

Study · id `cardio:ct-nct01197469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01197469](<https://clinicaltrials.gov/study/NCT01197469>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01197469

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT01197469. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT01197469, source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)
- Start date: 2010-09 (registry gives no type) (ClinicalTrials.gov record NCT01197469, source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01197469, source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)
- Completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01197469, source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)
- Countries: United Kingdom (ClinicalTrials.gov record NCT01197469, source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01197469-2012-11-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
- Condition: Chronic Obstructive Pulmonary Disease
- Condition: Pulmonary Hypertension
- Intervention (Drug): Tadalafil
- Intervention (Drug): Placebo
- Lead sponsor: University of Dundee
- Lead sponsor class: OTHER
- Collaborator: Chief Scientist Office of the Scottish Government
- Collaborator class: OTHER\_GOV
- Collaborator: NHS Tayside
- Collaborator class: OTHER\_GOV
- Collaborator: NHS Fife
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: University of Dundee (`cardio:org-university-of-dundee`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial (`cardio:pubmed-24717626`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 31ec5930a01e6a0c8458641e7a24b650201845da59906892f7e254d54e93cab2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
